Science

A Turning Point for Melanoma | FDA Approves Tudriqev Viral Therapy After Two Rejections

Replimune's herpes-based oncolytic virus Tudriqev won FDA accelerated approval with Opdivo for advanced melanoma resistant to anti-PD-1 therapy.

Jackson Yonwang · Aug 9, 2026